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Abstract 
Purpose:  To measure dispersion of a clinical proton therapy beam 
Methods and Materials: The proton center at our institution uses a Hitachi PROBEAT V 
synchrotron that delivers beams with energies ranging from 70 to 230 MeV to five treatment 
rooms, four of which have gantries and one fixed beam. For this study, the magnetic field 
strengths of all optics in the transport line were varied to measure the dispersion of 230 MeV 
beams in each of the four gantry rooms. Beam position was measured using the Spot Position 
Monitor (SPM), a multi-wire proportional counter (MWPC)   in the nozzle approximately 0.5 
meters upstream of the treatment isocenter. Measured beam positions as a function of momentum 
offset were fitted to a linear function to extract dispersion.  In one gantry, dispersions for 70 and 
140 MeV beams were also measured.  Because spot position is continuously monitored during 
treatments and a position deviation will abort the beam delivery, the dispersion at the spot 
position monitor was used to set an upper limit of range uncertainty originating from momentum 
deviation. When dispersion was approximately zero, dose rate measurements were used to set an 
upper limit of momentum deviation that could reach the patient.   
Results:  Dispersion was 0.45 m, 0.48 m and 0.30 m for 70 MeV, 140 MeV, and 230 MeV 
beams in a gantry, respectively, corresponding to 0.3 mm, 1.0 mm and 3.5 mm maximum range 
uncertainty during treatments. For 230 MeV beams, dispersion ranged from 0 to 0.73 m across 
the four gantries, corresponding to the upper limits of range uncertainty due to momentum 
deviation of 1.4 to 6.2 mm (0.4 to 1.9% in fractional range uncertainty). 
Conclusions: The measured dispersion was both energy- and gantry-dependent and ranged from 
0 to 0.73 m.  
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1 Introduction 
One of the advantages of proton therapy over photon therapy is spatial conformity. The finite 
range of the proton beam allows delivery of treatment essentially without an exit dose, resulting 
in reduced total energy deposited in the patient. However, the quality of proton therapy 
treatments relies on accurately understanding range uncertainty to properly evaluate the treated 
volume; underestimating range uncertainty may result in missing the tumor target due to the 
potential shift of the sharp distal dose fall-off, and overestimating range uncertainty may result in 
unnecessary irradiation of normal tissues.  
Primary sources of proton range uncertainty are the certainty of material stopping power and 
conversion of CT Hounsfield units (HU) to stopping power. Based on the Bethe-Bloch equation, 
the main parameters that drive the stopping power uncertainty are physical density and mean 
excitation energy1; density variation in the material and uncertainties from mean excitation 
energy for various heterogeneous media further add to the stopping power uncertainty. 
Additionally, uncertainties associated with assigning HU to relative stopping power increases the 
range uncertainty; measurement of HU numbers has uncertainty due to imaging parameters such 
as CT calibration and spatial resolution, and the conversion from HU to stopping power has 
uncertainty due to photon interaction cross-sections in the material that are not proportional to 
proton stopping power. A summary of these range uncertainties can be found elsewhere1. To 
account for the range uncertainties during treatment planning, the standard practice at our clinic 
is to study the treatment plan robustness to an uncertainty in the prescribed range of 3%.  
Another source of range uncertainty is the proton beam momentum uncertainty.  The theoretical 
range of a proton beam can be calculated by2, 
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𝑹𝑹(𝑬𝑬𝒊𝒊) = � 𝒅𝒅𝑬𝑬𝑺𝑺(𝑬𝑬)/𝝆𝝆𝑬𝑬𝒇𝒇𝑬𝑬𝒊𝒊  (1) 
where R is the range, Ei and Ef are the initial and final beam kinetic energy, and S(E)/ρ is the 
mass-stopping power as a function of energy. For 100 – 200 MeV proton beams, this equation 
reduces to 
R ≈ 0.00244E𝑖𝑖1.75  � gcm2� (2) 
where E𝑖𝑖 is in MeV. Fractional change in range due to change in beam momentum 𝑝𝑝 is  
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= 1.75 (𝛾𝛾 + 1)
𝛾𝛾
 𝑑𝑑𝑝𝑝
𝑝𝑝
 
(3) 
 where γ is the relativistic gamma. A plot of range shift as a function beam energy and 
momentum offset are shown in Figure 1.  For 70 to 230 MeV beams, 
(𝛾𝛾+1)
𝛾𝛾
= 1.93 to 1.80, respectively.  Therefore, as a rule of thumb: 
𝑑𝑑𝑑𝑑
𝑑𝑑
≈ 3.3 𝑑𝑑𝑑𝑑
𝑑𝑑
. 
For the highest beam energy clinically used at our institution, 230 MeV, a 0.3% momentum 
deviation leads to a change in range of approximately 1% or 3 mm.  It has been suggested that 
small momentum acceptance in a proton therapy accelerator will prohibit beams from reaching 
the patient when there is a considerable energy deviation3,4. In this technical note, we report 
measurements of the upper bound on momentum deviation that can reach a patient during 
treatment.  
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Figure 1: Change in range as a function of beam energy for three different momentum offset. 
 
2 Background 
Beam steering in an accelerator is performed by applying Lorentz forces, and the effects of the 
magnetic fields depend on particle momentum. If the particle momentum is slightly offset from a 
reference momentum or if the particle beams are not monochromatic, then the deflection of a 
particle with the wrong energy will deviate from the trajectories of a particle with a nominal 
momentum. The variation in the deflection in a bending magnet caused by a momentum error is 
called the dispersion, and consequently, the dispersion is present only in the bending plane of the 
dipole magnets, which is specified as the 𝑥𝑥-axis in this report. The magnitude of the positional 
deviation is characterized by5 
∆𝑥𝑥 = 𝐷𝐷𝑥𝑥(𝑠𝑠)𝛿𝛿, (4) 
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where ∆𝑥𝑥 is the shift from the reference trajectory, 𝛿𝛿 = (𝑝𝑝 − 𝑝𝑝0)/𝑝𝑝0 is the fractional momentum 
offset of the beam, 𝑝𝑝0 is the nominal beam momentum set by the magnets, and 𝐷𝐷𝑥𝑥(𝑠𝑠) is the 
dispersion function at location s.  
Typically, beam range is measured periodically as a part of beam energy quality assurance6, but 
the spot position is always measured by the SPM during treatment. If dispersion is not zero at the 
spot position monitor, the delivered spot position with respect to a nominal position can be used 
to set an upper bound on momentum deviation. Range variation due to the momentum offset can 
then be calculated using Equation (3). Experimentally, the dispersion can be measured by 
changing the beam momentum 𝑝𝑝 or by changing the magnetic field strengths. Magnetic rigidity, Bρ = 𝑝𝑝0𝑐𝑐/𝑞𝑞𝑞𝑞, defines the required magnetic field strength for a given bending radius and 
particle momentum, where B is the magnetic field, ρ is the bending radius, 𝑝𝑝0is the reference 
momentum, 𝑐𝑐 is the speed of light, and 𝑞𝑞𝑞𝑞 is the charge of particles. By changing the magnetic 
field strengths B, we can in effect adjust the nominal momentum 𝑝𝑝0for a given bending radius ρ. 
When a shift in beam position ∆𝑥𝑥 is measured as a function of 𝑝𝑝 or 𝑝𝑝0, dispersion can be 
calculated using Equation (4) at the given location. 
3 Materials and Methods 
The proton center at our institution uses  the Hitachi PROBEAT V synchrotron that delivers 
beams from 70 to 230 MeV for five treatment rooms, four of which have gantries: Gantries 1 – 4. 
All gantries utilize pencil beam scanning delivery with an identical gantry design. Protons are 
extracted from the synchrotron and transported through series of quadrupole magnets and dipole 
magnets to the treatment isocenter. A simplified schematic of our beam transport line is shown in 
Figure 2. In the transport line, to first order, the source of dispersion is entirely from the series of 
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four bending magnets indicated with blue arcs in Figure 2. Assuming that the beam is on a 
reference trajectory at the time of extraction from the synchrotron, the beam position deviation 
due to dispersion occurs only after the first bending magnet. Beam position is measured using the 
Spot Position Monitor (SPM) positioned at approximately 0.5 meters upstream of the treatment 
isocenter. The SPM is always in the beam line to measure both spot position and width during 
treatments.  The control system will abort the beam delivery if the spot position deviates from 
the planned position by more than a set tolerance level at the SPM during treatments.  The 
tolerance is comprised of both a random and systematic component7, but we will simply use ± 1 
mm for this study.  Additionally, dose rate is calculated by dividing the delivered monitor unit by 
the delivery time for each spot, both measured by the dose monitoring ion chamber. The dose 
monitoring ion chamber is located immediately upstream of the SPM as indicated in Figure 2. 
The field delivery timer will abort a beam if the delivery takes longer than 120% of nominal 
delivery time during treatments. Spot position, width and beam delivery timer interlocks were all 
turned off during the experiment to allow measurements outside of treatment tolerances. 
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Figure 2: Simplified schematic (not to scale) of beam transport line in our proton therapy 
accelerator complex.  
 
In this study, we varied the magnetic field strengths of all optics in the transport line to measure 
the beam dispersion. The magnet currents for these beam transport optics are linearly 
proportional to magnetic field strengths and were varied by ±0.3% from the nominal values to 
modify the momentum offset 𝛿𝛿. For each magnet setting, 300 spots of 0.04 monitor units were 
delivered to the isocenter and the beam profile was measured with the SPM.  For each spot, the 
peak of the measured profile – defined as >30% of the peak intensity – was fitted to a Gaussian 
distribution to extract spot position and width. Positional shift ∆𝑥𝑥 was defined as the deviation 
from nominal spot position which was defined as the average spot position for 𝛿𝛿 = 0. The 
average shifts as a function of momentum offset 𝛿𝛿 were fitted to a linear function to measure the 
dispersion at the SPM. Dose rate was used to evaluate if the beam was clipped in the transport 
line. The measured dose rate was normalized by the average dose rate for the nominal 
momentum, 𝛿𝛿 = 0. When beam clipping was suspected based on the decreased dose rate, the 
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data points were excluded from the linear fit for the dispersion measurement. If dispersion was 
not zero at the SPM, changes in beam range corresponding to spot position deviation of 1 mm 
were calculated as an upper limit of range uncertainty due to momentum deviation during 
treatments. When dispersion was approximately zero at the SPM plane, dose rate measurements 
were used to set an upper limit of momentum deviation that could potentially reach the patient.  
The measurements were performed for three beam energies -- 70 MeV, 140 MeV and 230 MeV 
– in Gantry 4. For the highest beam energy, the measurements were obtained for all four gantries.  
4 Results 
Beam position shift ∆𝑥𝑥 at the SPM in the bending plane (𝑥𝑥-axis) as a function of 𝛿𝛿 measured for 
three different beam energies is shown in Figure 3 (a). The error bars indicate the standard 
deviation of the 300 spots for the reference momentum setting and that of momentum offset 
summed in quadrature. Dispersions measured by linear fit to the data are summarized in Table 1.  
Changes in range corresponding to 1 mm positional shifts at the SPM are also listed in Table 1. 
For the nominal momentum, 𝛿𝛿 = 0, spot position deviation for each of the 300 spots is shown in 
Figure 3 (b), illustrating the drift of the spot position.  The sudden change in spot position near 
the beginning of the spill in the 230 MeV data which is not observed in the 70 or 140 MeV data 
is suspected to be due to the synchrotron magnet control system8.    The gradual drift in spot 
position over the course of the spill is likely due to the drift in the nominal momentum of the 
extracted phase space.   Measured dose rate for δ = −0.3%, 0%, 0.3% are shown in Figure 4. 
For 70 MeV and 140 MeV, beam was clipped for 𝛿𝛿 = 0.3%, and the decreased dose rate is seen 
in Figure 4 (a, b). For 230 MeV, no obvious change in dose rate was observed for all momentum 
settings. 
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Figure 3: Spot position measurement for three different beam energies in gantry 4. (a) Average 
spot position for the 300 spots as a function of momentum offset, 𝛅𝛅. (b) Spot position for each of 
the 300 spots for 𝛅𝛅 = 𝟎𝟎.  
 
Table 1: Dispersion and maximum range variation corresponding to the 1 mm positional 
tolerance at the SPM measured in Gantry 4. 
 Dx (m) dRmax (mm) dRmax/R 
70 MeV 0.45 0.3 0.8% 
140 MeV 0.48 1.0 0.7% 
230 MeV 0.30 3.5 1.1% 
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Figure 4: Normalized dose rate for each of the 300 spots for 𝛅𝛅 = −𝟎𝟎.𝟑𝟑%,𝟎𝟎%,𝟎𝟎.𝟑𝟑%. The nominal 
dose rate is defined as the average dose rate for 𝛅𝛅 =  𝟎𝟎%. 
 
Beam position shift at the SPM as a function of 𝛿𝛿 for 230 MeV beams in all four gantry rooms 
are shown in Figure 5. For Gantry 2 through 4, the dispersions at the SPMs measured by the 
linear fit are summarized in Table 2.  For Gantry 1, dispersion was approximately zero at the 
SPM. However, as shown in Figure 6, measured dose rate starts to decrease for δ ± 0.5% and 
decreases significantly for 𝛿𝛿 = ±0.6%, indicating that the beam was being clipped in the 
transport line. For 𝛿𝛿 ± 0.7%, the beam failed to  reach the treatment room, even with the beam 
12 
 
delivery interlocks turned off.  This occurred due to non-zero dispersion in the beam line 
upstream of the SPM. Due to the nature of dipole optics, the location of maximum dispersion 
would occur between GB1 and GB2 dipole magnets for all four gantry rooms5.  The beam is lost 
at this point of maximum dispersion because of the finite diameter of the beam pipe. The 
momentum shift of 𝛿𝛿 = 0.6% for the 230 MeV beam corresponds to a 6.2 mm change in range 
or 1.9% in fractional change in range. For gantries 2 through 4, the normalized dose rate was 
similar to what is shown in Figure 4 (c); no obvious beam clipping was observed for 𝛿𝛿 ± 0.3%. 
 
Figure 5:  Spot position shifts at the SPM for 230 MeV beam in all four gantries. 
 
Table 2: Dispersion and maximum range variation corresponding to the 1 mm positional tolerance at the 
SPM for 230 MeV. *Upper limit calculated for 𝜹𝜹 = 𝟎𝟎.𝟔𝟔%, where we observed a decrease in dose rate. 
 Dx (m) dRmax (mm) dRmax/R 
Gantry 1 -- 6.2* 1.9% 
Gantry 2 0.58 1.8 0.5% 
Gantry 3 0.73 1.4 0.4% 
Gantry 4 0.30 3.5 1.0% 
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Figure 6: Measured dose rate in Gantry 1 for 𝛅𝛅 = 𝟎𝟎%, ±𝟎𝟎.𝟓𝟓%, ±𝟎𝟎.𝟔𝟔%. 
 
5 Discussion 
In this study, we measured dispersion at the SPM for our highest beam energy in all four gantries, 
and we measured the dispersions of three beam energies in Gantry 4. Dispersion was both 
gantry- and beam energy-dependent. Spot position tolerance of ± 1 mm sets an upper limit of 
range uncertainty originating from momentum deviation: 0.3 mm for the 70 MeV and 3.5 mm 
for the 230 MeV beams in Gantry 4. Furthermore, dispersion at the SPMs varied across the four 
gantries. For Gantries 2 through 4, upper limits of range uncertainty due to momentum deviation 
were 1.4 to 3.5 mm or 0.4 to 1.0% in fractional range uncertainty. For Gantry 1, where 
dispersion was approximately zero at the SPM, dose rate measurements indicated that 
momentum offset of 𝛿𝛿 = 0.6% clips the beam, which would abort the delivery based on the field 
delivery timer.  The momentum shift of 0.6% for the 230 MeV beam corresponds to a 6.2 mm 
change in range. The upper limit of range uncertainty is likely an overestimate because the 
analysis assumes that spot position deviation is solely caused by momentum deviation. However, 
understanding dispersion at the SPM and the momentum acceptance of the transport line is a 
valuable consideration for the patient safety.  
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Ideally, spot position deviation would be measured at a location with a large dispersion function 
to achieve high sensitivity to deviations in momentum. Since gantries are generally designed to 
have zero or very small dispersion at the treatment isocenter, measuring spot position closer to 
the treatment isocenter would likely decrease the sensitivity of this dispersion test.  Continuous 
monitoring of beam position at the largest dispersion location in the accelerator complex using a 
passive beam position monitor would be ideal. However, in a capacitive coupling device, low 
beam currents in our transport line -- on the order of a few hundred nano-amps -- would generate 
only a small signal that would likely be lost in the noise9. Another possibility to decrease the 
variation in particle range potentially reaching the patient is to reduce the diameter of the beam 
pipe at the position of largest dispersion.  This option seems attractive because then one could 
eliminate the SPM to reduce multiple scattering in the nozzle and therefore decrease the spot size 
to the patient.  However, one would likely still wish to retain the SPM to measure the spot size 
and to have a confirmation of the spot scanning magnetic fields. 
Finally, it is worth noting that there are accelerators with a large momentum acceptance, such as 
fixed-field alternating gradient accelerators, which would be less sensitive to momentum 
deviation by design10,11. For these accelerators, assuring the beam energy reaching the patient 
would still be necessary to ensure patient safety.  
6 Conclusions 
We measured beam dispersion in our clinical proton therapy system 0.5 m upstream of treatment 
isocenter. The dispersion was both beam energy- and gantry-dependent. Measured dispersion 
ranged from 0 – 0.73 m across the four gantries for 230 MeV beams.  
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